GlassScriptPhysician profile
Andrew Y Soh
NPI 1649276189
$1,981.67
in general payments reported to CMS, 2019-2025
21 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2021: $237 · 2022: $33.40 · 2023: $298 · 2024: $946 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.20 |
| Education | $208.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $296.53 | 2019-2024 | Tagrisso |
| Pfizer INC. | $216.31 | 2024 | |
| Daiichi Sankyo INC. | $185.40 | 2022-2024 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $177.57 | 2021-2024 | Erleada, Carvykti, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $170.99 | 2019-2021 | |
| Celgene Corporation | $114.22 | 2025 | Reblozyl |
| Abbvie INC. | $106.72 | 2024-2025 | |
| Medical Device Business Services, INC. | $100.00 | 2019 | |
| Amgen INC. | $99.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.79 | 2024-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $84.44 | 2024 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $71.06 | 2024 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $55.98 | 2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $40.05 | 2024 | |
| Ucb, INC. | $37.02 | 2024 | Rystiggo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.50 | 2024 | Xtandi |
| Lilly USA, LLC | $22.51 | 2024 | Retevmo, Jaypirca, Verzenio |
| Beigene USA, INC. | $22.03 | 2024 | Brukinsa |
| Fennec Pharmaceuticals, INC. | $20.27 | 2023 | Pedmark |
| Alnylam Pharmaceuticals INC. | $18.84 | 2024 | Onpattro |
| Myriad Genetic Laboratories, INC. | $18.49 | 2024 | Precisetumor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Soh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.